BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30963603)

  • 1. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
    Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
    Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
    Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
    Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
    Capurro M; Martin T; Shi W; Filmus J
    J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma.
    Hu P; Ke C; Guo X; Ren P; Tong Y; Luo S; He Y; Wei Z; Cheng B; Li R; Luo J; Meng Z
    Dig Liver Dis; 2019 Jan; 51(1):120-126. PubMed ID: 30001951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
    Zittermann SI; Capurro MI; Shi W; Filmus J
    Int J Cancer; 2010 Mar; 126(6):1291-301. PubMed ID: 19816934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/β-catenin signalling activation.
    Gong T; Ning X; Deng Z; Liu M; Zhou B; Chen X; Huang S; Xu Y; Chen Z; Luo R
    J Cell Biochem; 2019 Oct; 120(10):16934-16945. PubMed ID: 31104336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
    Capurro MI; Xiang YY; Lobe C; Filmus J
    Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
    FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New tumor suppressor microRNAs target glypican-3 in human liver cancer.
    Cartier F; Indersie E; Lesjean S; Charpentier J; Hooks KB; Ghousein A; Desplat A; Dugot-Senant N; Trézéguet V; Sagliocco F; Hagedorn M; Grosset CF
    Oncotarget; 2017 Jun; 8(25):41211-41226. PubMed ID: 28476031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.
    Bi Y; Jiang Y; Li X; Hou G; Li K
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):499-505. PubMed ID: 33225417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
    Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
    Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
    Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
    Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
    Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.
    Cheng W; Tseng CJ; Lin TT; Cheng I; Pan HW; Hsu HC; Lee YM
    Carcinogenesis; 2008 Jul; 29(7):1319-26. PubMed ID: 18413366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.
    Lai JP; Sandhu DS; Yu C; Han T; Moser CD; Jackson KK; Guerrero RB; Aderca I; Isomoto H; Garrity-Park MM; Zou H; Shire AM; Nagorney DM; Sanderson SO; Adjei AA; Lee JS; Thorgeirsson SS; Roberts LR
    Hepatology; 2008 Apr; 47(4):1211-22. PubMed ID: 18318435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.